Apax and Merlin lead $30m round in Neurotech
Apax Partners and Merlin Biosciences led a $30m round of financing in Neurotech, which develops cell-based therapy.
New investors Apax Partners, Merlin Biosciences, Westdeutsche Landesbank Girozentrale, ABN Amro, Rothschild and AGF Innovation invested alongside previous investors 3i, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, GIMV, and IMH.
Neurotech said the money would be used to finance clinical trials.
The company believes the new money will last about three years, but also said it would consider an IPO depending on market conditions.
Laurent Ganem of Apax and Mark Clement of Merlin have taken seats on Neurotech's board of directors.
3i and SEB Foretagsinvest invest in Arexis
3i and SEB Foretagsinvest have invested $4.5m in Swedish firm Arexis.
New investors 3i and SEB Foretagsinvest each invested $1.9m and previous investors InnovationsKapital and individuals invested $378,000.
Arexis also said it received $472,000 in convertible debt financing from the Swedish Industrial Development Fund.
The Henburg-based company said the money would go on research. It is expected to last about two years.
Laurie Rostron of 3i and Johan Christenson of SEB joined the board of directors.
3i invests in Fractus
3i has invested about E5m in Fractus.
Barcelona-based Fractus, which develops multiband antenna technology also received $429,000 from venture firm Barcelona Empren.
3i will hold a 20 per cent stake in Fractus.
The company said the capital would go towards expansion in Europe.
Fractus plans to reach profitablity by the end of the year.